Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective-Reference-Cited by-同舟云学术

Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective

Published:2024-07-12 Issue:14 Volume:16 Page:2526
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Ladwa Rahul¹²,Fogarty Gerald³,Chen Peggy⁴⁵,Grewal Gurpreet⁶,McCormack Chris⁷^ORCID,Mar Victoria⁸⁹,Kerob Delphine¹⁰^ORCID,Khosrotehrani Kiarash¹¹¹²

Affiliation:

1. Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD 4102, Australia

2. Faculty of Medicine, University of Queensland, Herston, QLD 4006, Australia

3. Icon Cancer Centre Revesby, Revesby, NSW 2212, Australia

4. Peggy Chen Skin Cancer and Mohs Surgery, New Plymouth 4310, New Zealand

5. Te Whatu Ora Health New Zealand Taranaki, Westtown, New Plymouth 4310, New Zealand

6. McGrath Foundation Breast Care Nurse, Alfred Health, Cancer Services, Melbourne, VIC 3127, Australia

7. Department Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia

8. Victorian Melanoma Service, Alfred Health, Melbourne, VIC 3004, Australia

9. School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3800, Australia

10. La Roche-Posay International, 92300 Levallois, France

11. Dermatology Research Centre, Experimental Dermatology Group, Frazer Institute, The University of Queensland, Woolloongabba, QLD 4072, Australia

12. Department of Dermatology, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia

Abstract

Cancer systemic therapeutics and radiotherapy are often associated with dermatological toxicities that may reduce patients’ quality of life and impact their course of cancer treatment. These toxicities cover a wide range of conditions that can be complex to manage with increasing severity. This review provides details on twelve common dermatological toxicities encountered during cancer treatment and offers measures for their prevention and management, particularly in the Australian/New Zealand context where skincare requirements may differ to other regions due to higher cumulative sun damage caused by high ambient ultraviolet (UV) light exposure. Given the frequency of these dermatological toxicities, a proactive phase is envisaged where patients can actively try to prevent skin toxicities.

Funder

La Roche-Posay, a L’Oreal company

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/14/2526/pdf

Reference70 articles.

1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA A Cancer J. Clin.,2024

2. Cancer Australia (2023, September 01). Cancer in Australia Statistics, Available online: https://www.canceraustralia.gov.au/impacted-cancer/what-cancer/cancer-australia-statistics#:~:text=In%202022%2C%20it%20is%20estimated,by%20the%20age%20of%2085.

3. Zealand, H.N. (2023, September 01). Cancer Web Tool, Available online: https://www.tewhatuora.govt.nz/our-health-system/data-and-statistics/nz-health-statistics/health-statistics-and-data-sets/cancer-data-and-statistics/cancer-web-tool/.

4. Management of skin adverse reactions in oncology;Silva;J. Oncol. Pharm. Pract.,2020

5. Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae;Wagner;Oncology,2007